findings last of mRNA. bivalent boosted that and consistency vaccine. Thanks, data. of evaluated three study lot amount vaccine Omicron a preliminary three boosting is vaccine doses review vaccine, have to a developed I'll on when change that study Study and on new XXX, Stan. our significant strain top XXX, I'm call, responses the top Today, to which to going given from of Since of BA.X we prototype doses Then, mRNA describe of our includes lot clinical data from two
alpha UK Please the cases had majority to advance review all we I want that being slide findings caused to This of period. our recently disclosed. have our six-month efficacy was for by infections we recently first, study, despite From preventing variant. some over XX% seven. But published vaccine observation the
Protection sequelae from infection is can't don't important, you can't of get get COVID, get for and you the because source can't and long can't you COVID infected, you variants. if you virus, new transmit be
cross-reactive endpoint boosting we US-Mexico in demonstrated response, our studies. a the associated Omicron X formal variants that we a durable levels against were antibody with broad directed regulatory as immune Phase well with In supporting a protection and US our study, that consistent adult response as in Phase levels immune achieved X population, includes
Phase hemologic with comparable XX XX-year-olds for adolescents associated to variants made we boosting to show Omicron were X endpoint regulatory study, protection. our the those responses the in to and In
Okay.
go and about study. which to to lot Study our consistency talk Let's XXX, lot slide eight is
endpoint For boosting This is data ongoing. and response. magnitude our discuss assessment this immunologic achievement the additional study, the lot-to-lot preliminary and I'll of heterologous data the of still is breadth supporting and
US move let's least to please. had no and three So the prior doses of COVID slide months six who nine, being history who recent at enrolled COVID infection in of approved XXX last to vaccine Study two dose adults XXX or with the enrollment. an received had
subjects you slide, either this can most received or two three see As of Pfizer. of on doses Moderna our or
one collected doses number of of two vaccine hemologic of doses J&J received and XX a at received were boosted different for subjects serum you with enrollment, or was of very had lots After day all the Novavax. two Novavax If one three small assessment. and
show balanced. the interval groups months. the lot Let's population were was the makeup prior move and to three slide XX. the approximately well US nine The to representative boost median broadly general of was Novavax racial Demographics
look to endpoint. and go XX Let's slide primary the at
of endpoint the regulatory This confirming As titers was at our XX. measured you achieved, primary of the day non-inferior consistency can process. see was as by endpoint here, IgG immunogenicity manufacturing anti-S
intervals You can extremely please here. note confidence tight the
evaluate booster, the the But Because a trial slide and Novavax boosting we in most in the received please. following different heterologous on at the magnitude and let's the as subjects breadth opportunity immunogenicity look subsets. XX, had of immune heterologous to responses homologous this of vaccine
Novavax Shown for group does a Pfizer, a series dose seven single who of responses received of one subjects Novavax's J. also doses showing those followed and two boost. of J& received prior are responses who on of small left two Moderna, the We're priming prior far doses of in IgG by two
based observed matched the study. obtained with levels derived the X actual saw trial seen Phase we've imposed levels studies. the Phase X the Phase homologous in The or our boosting this US US we X for Consistent we and by in levels antibody efficacy the protection on post-booster the in closer super a Novavax what previously, titers we achieved government A our X subset. highest exceeded two trial threshold Phase
XX doses heterologous Pfizer doses received go mRNA. or of of or Moderna the prior two This set doses to three J&J. look prior but at the group's for three and up let's Okay, of boosting top previous is on of similar to a slide slide,
course So, prior plus a primary full boost. one
exceeded previous III mRNA the just the antibody because was these of sample slide of levels XX% to of Phase intervals of the mRNA. J&J saw levels two in levels. with each broad with XX% than recipients size. we for And were two conference higher small had group doses In the approximately priming doses The subsets, the
of look at to slide Now, look immune let's the at response. breadth XX
on bar to Novavax. the boosted hand three we solid X. once once doses of Here, and each compared the we or BA.X And Novavax side left of sub-variants displaying as evaluated IgG three far Novavax Pfizer are responses triplet. of Moderna doses doses to Omicron boosted as with with prototype and to two a of
cases, all or achieved predicted to was be protection titers approximately IgG XX% levels to In XX%.
the prototype both Novavax before, and antibody boosted in subjects. As titers homologous highest variants against were
consistency studies. both with and variants heterologous after showed our summary, important are believe the which the those life because because levels antibody in protection with vaccine and findings robust they immune critical homologous levels we responses and associated approximating insured In boosting they for post-boosting XXX confirm X manufacturing, prototype Phase is in US of to
move study. to the next talk about let's XX So, and slide
prototype vaccine from vaccine vaccine Now, BA.X and was mRNA. study a I'll given two data doses study review strain XXX. evaluated our change the of bivalent three designed The format when after as and a performance the and and Omicron study of topline
Today, two So, years adults of XX with mRNA to were three age. in at boosted design. only or boosted the who their three vaccine, prototype our either days least in and the vaccine. participants and The of XX, The bivalent or I who doses Australia conducted prior of was the let's after doses to go received XX BA.X XX about last talk slide dose. mRNA vaccine, received participants will study are
the boost with days study overall XX. balanced facial the dose. representative of let's received after population, look on at slide are The of well groups So, the median participants group's mRNA XXX their last Australian their demographics
COVID did that controlling of prior You better of Australia a large did infection. can have proportion of is this see infection a job group relatively not evidence
against in let's to was BA.X had endpoints slide prior look no The We the and responses portion compared COVID be who treatment primary group infections. at day XX three-dose the the change three for XX. on groups. So, the pre-specified participants strain a endpoint in neutralizing
the a BA.X first column, strain achieved than with after prototype endpoint. we if because strain change vaccine, BA.X the boosted were study In a needed. a statistical induced was responses vaccine higher in compare And vaccine the after allowing for BA.X the the to BA.X with endpoint, change, closed This being BA.X prototype. being responses boosted responses eventually against by those
click. a get Let's
The intervals with The second were column the column prototype. final to overlapping lower bivalent a were compares for similar, the And vaccine. the compares to bivalent responses one. and the bivalent vaccine responses vaccine the the BA.X conference vaccine
have Let's click. a
So a go, the as BA.X does responses far as bivalent data vaccine. support the the for benefit measurable not
Okay.
Let's slide look XX. at some comparative on data
looking against population. responses at and the BA.X prior group vaccine. who most received we're doses resembles the IgG of This all participants closely mRNA Here, general three
the vaccines. Here, similar responses three were all between
with was higher numerically XX%. by boosted prototype, it when Although, our about
Please to slide advance XX.
to again, XX% were against Wuhan numerical strain. Here, we're a with comparable, prototype the boosting vaccine. the responses looking Once at for prototype with IgG benefit responses up statistically the
circulation are BA.X nor prototype neither course, in Of currently.
BA.X please. that BA.X an Displayed in expect is omicron BA.X, with in would any a not against was vaccine. at look response but XX, here it's vaccines, related forward pseudoneutralization functional let's so Slide assay. neutralization a subvariant BA.X of we the different to response measured superior strains. So the is
no observed vaccine. prototype the either BA.X there compared the bivalent benefit vaccine However, vaccine to for nor was
prototype that the variants. a higher fact, be and vaccine is viable a vaccine our boosting current responses. with emerging approach This as for In get considered indicates strategy future-proof numerically
reactogenicity Okay, formulations, boost slide as patterns When a tolerated what we've dose at similarly second for some previously. three on seen all let's well to consistent they look given with were XX.
severity. mild the Here moderate pain common tenderness, none, are being the are majority in local or most reactions in vast
look we've to and what systemic three slide rates at low events go a XX very negligible of previously, pattern also with symptoms, similar seen is the solicited to very fever and and signal. Let's grade
Okay.
on up slide this XX. sum Let's
durable using Omicron levels achieved believe consistent booster. data sum our have associated as Phase use the continued study response our our with levels we vaccine, described a our the Phase future X and against studies. US-Mexico with were From prototype to in data drifted we the immune a So of indicating supports up, and hemologic X protection NVX-XXXX that variants
data immune are the And you protection we drifted of magnitude protective showed variants. or to are applying booster doses achieved two NIH the I calls be a after authorized responses we US that responses of Today, when against thresholds. vaccine, heterologous when Omicron used considered as government three broad of these
our vaccine measurable indicated with benefit BA.X vaccine study Omicron and our Finally, bivalent vaccine. no over prototype
illness few be BA.X, The high where about over next effort. not the months, levels variant of think boosting some it what as we future-proof when So is might will responses will be to that there's causing a way the yet appealing to induces emerge. vaccine cross-variant ongoing that
Importantly, can be and the immediately. stocked deployed currently is vaccine
preexisting hesitant a Finally, be our feature individuals because safety attractive confidence in that's database. long-lived boosted. we be is vaccine, are the who have This may to original to this
Okay.
me Let it turn Trizzino. John over to
